Can bone morphogenetic protein binding peptide increase efficiency of bone formation?

Spine

Volumn 35, Issue 17, 2010, Pages 1655-1659

  McGovern, Scott C ^a   Fong, Winston ^a   Wang, Jeffrey C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adjuvant; BBP; bone morphogenetic binding peptide; spinal fusion

Indexed keywords

BINDING PROTEIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN BINDING PEPTIDE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ARTHRODESIS; ARTICLE; DRUG HALF LIFE; DYSPHAGIA; FRACTURE HEALING; HEMATOMA; HUMAN; NECK SWELLING; OSSIFICATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; SPINE FUSION; SWELLING;

BONE MORPHOGENETIC PROTEINS; HUMANS; OSTEOGENESIS; SPINAL FUSION;

EID: 77955466173     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181e83c93     Document Type: Article

References (30)

1. Carlisle E, Fischgrund JS. Bone morphogenetic proteins for spinal fusion. Spine J 2005;5:240S-9S.
2. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-241
3. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83(suppl 1):S151-8.
4. Kanakaris NK, Giannoudis PV. Clinical applications of bone morphogenetic proteins: current evidence. J Surg Orthop Adv 2008;17:133-146
5. Mulconrey DS, Bridwell KH, Flynn J, et al. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion. Spine 2008;33: 2153-2159
6. Johnson EE, Urist MR, Finerman GA. Distal metaphyseal tibial nonunion. Deformity and bone loss treated by open reduction, internal fixation, and human bone morphogenetic protein (hBMP). Clin Orthop Relat Res 1990: 234-240
7. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-899
8. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009;302:58-66.
9. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 2008;62: ONS423-31; discussion ONS31.
10. Glassman SD, Carreon LY, Campbell MJ, et al. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion. Spine J 2008;8: 443-448
11. Glassman SD, Carreon LY, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine 2008;33:2843-2849
12. Miyamoto S, Takaoka K, Yonenobu K, et al. Ossification of the ligamentum flavum induced by bone morphogenetic protein: an experimental study in mice. J Bone Joint Surg Br 1992;74:279-283
13. Perri B, Cooper M, Lauryssen C, et al. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. Spine J 2007;7:235-239
14. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006;31:542-547
15. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 2006;31:2813-2819
16. Vaidya R, Carp J, Sethi A, et al. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J 2007;16:1257-1265
17. Vaidya R, Sethi A, Bartol S, et al. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech 2008;21:557-562
18. Martin GJ Jr, Boden SD, Marone MA, et al. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 1999;12: 179-186
19. Boden SD, Schimandle JH, Hutton WC. 1995 Volvo Award in basic sciences. The use of an osteoinductive growth factor for lumbar spinal fusion. Part II: study of dose, carrier, and species. Spine 1995;20:2633-2644
20. Alanay A, Chen C, Lee S, et al. The adjunctive effect of a binding peptide on bone morphogenetic protein enhanced bone healing in a rodent model of spinal fusion. Spine 2008;33:1709-1713
21. Lu SS, Zhang X, Soo C, et al. The osteoinductive properties of Nell-1 in a rat spinal fusion model. Spine J 2007;7:50-60.
22. Behnam K, Phillips ML, Silva JD, et al. BMP binding peptide: a BMP-2 enhancing factor deduced from the sequence of native bovine bone morphogenetic protein/non-collagenous protein. J Orthop Res 2005;23:175-180
23. Urist MR, Huo YK, Brownell AG, et al. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci U S A 1984;81:371-375
24. Sintuu C, Murray SS, Behnam K, et al. Full-length bovine spp24 [spp24 (24-203)] inhibits BMP-2 induced bone formation. J Orthop Res 2008;26: 753-758
25. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein- 2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 2003;28:1219-24; discussion 1225.
26. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006;19:483-486
27. Burkus JK, Boden SD, Toth J, et al. Short term effects of rhBMP-2/absorbable collagen sponge in a cancellous bone environment. Spine J 2006;6:1S-161S.
28. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002;27:S66-85.
29. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002;84:1032-1044
30. He W, Zhang X, Wu G, et al. The adjunctive effect of BBP on BMP-2 decreased local inflammatory reaction in a rodent model. In: Annual Meeting of the American Academy of Orthopedic Surgeons; February 25-28, 2009; Las Vegas, NV